Suven Life Sciences Ltd (SUVEN) is currently trading at 334.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Suven Life Sciences Limited is a clinical-stage biopharmaceutical company primarily focused on developing novel therapeutics for neurodegenerative disorders. Its operations include Contract Research And Manufacturing Services (CRAMS), offering process research, clinical trial supplies, and exclusive manufacturing services. The company has expanded its drug discovery into areas such as Major Depressive Disorder, pain management, and obesity, showcasing its specialization in CNS-based programmes. Suven's subsidiary, Suven Neurosciences, Inc., USA, is dedicated to advancing clinical studies of Suven molecules, indicating significant investments in international operations related to CNS therapies. In FY15, Suven entered into an exclusive licensing agreement with Taro Pharmaceuticals for its Malathion lotion, expected to yield revenue and royalties from the US, Canada, and Mexico markets. Several new molecules have been added to Suven's drug pipeline, with significant investments in R&D and clinical trials, reinforcing their commitment to addressing niche medical needs.

Over the past 52 weeks, Suven Life Sciences Ltd has traded between a low of ₹124.35 and a high of ₹402.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Suven Life Sciences Ltd has a market capitalization of approximately 10,025.32. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Suven Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 10,025.32 Cr, Suven Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Suven Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Suven Life Sciences Ltd is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The provided quarterly table lists a consolidated net loss of ₹127.61 crore for Q1FY27, compared with ₹51.52 crore in Q1FY26.

After reviewing unblinded safety data from about half the participants who completed 12 weeks of treatment, the DSMB found no safety concerns and recommended the trial continue without modifications.

Management expects key readouts in 2027, led by Phase 3 data for SUVN-502 (Masupirdine), with other pipeline molecules also discussed as approaching major results around the same period.